Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) released its Quarterly 4C Report for the three-month period ended 31st March 2020. The key highlights for the March 2020 quarter include:
- Grant of HER-Vaxx immunotherapy patent in US.
- Completion of PD1-Vaxx GMP manufacturing.
- Completion of PD1-Vaxx preclinical toxicology studies, which confirmed PD1-Vaxx produces high levels of PD1-targeting antibodies.
- New publication on CF33 (Vaxinia) from Professor Yuman Fong.
With research and development expenditure of $2.2 million during the quarter, the Company reported a cash balance of $33.7 million as at 31st March 2020.
IMU traded at $0.023 on 27 April 2020 (12:59 PM AEST).
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
